Humanized vascular endothelial growth factor (VEGF) antibody (bevacizumab; Avastin) is a highly effective monoclonal antibody against metastatic colorectal cancer and several other advanced late stage cancers.
|Cell lines||NSCLC cell lines|
|Preparation method||Six NSCLC cell lines were seeded (~2,000–5,000 cells per well, depending on cell type) onto 96-well plates. After 24 h of incubation, cells were treated with erlotinib (0–20 µmol/L), bevacizumab (0–20 ng/mL) or a combination of these agents (erlotinib 1 µmol/L; bevacizumab 10 ng/mL) for 72 h in serum-containing medium. The viability was determined by MTS assay (Promega, Madison, WI) according to the manufacturer’s instructions.|
|Incubation time||72 h|
|Animal models||Female Wistar rats|
|Formulation||0.9%sodium chloride solution|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||10 mM in DMSO|
Effect of Avastin on the migration and invasion of pterygium fibroblasts.
Liu W, et al. Eye Sci. 2014 Dec;29(4):214-8. PMID: 26016073.
Injectable biodegradable hydrogels from vitamin D-functionalized polycarbonates for the delivery of avastin with enhanced therapeutic efficiency against metastatic colorectal cancer.
Lee AL, et al. Biomacromolecules. 2015 Feb 9;16(2):465-75. PMID: 25543531.
Glutaminase C-IN-1 (968) is an allosteric inhibitor of Glutaminase C that inhibits cancer cell growth without affecting their normal cellular counterparts.
NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 μM in a cell-free assay; does not inhibit the closely related targets, Cdc42 or RhoA.
Budesonide is a GC steroid commonly used for the treatment of asthma and non-infectious rhinitis.
Brequinar is a potent inhibitor of dihydroorotate dehydrogenase, with potent activities against a broad spectrum of viruses.
Laropiprant is a potent, selective DP1 receptor antagonist with Ki value of 0.57 nM, and exhibits > 1,000 fold selectivity over DP2 receptor (Ki=0.75 μM).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.